In support, the CD46 was either shown to be expressed in tumor tissues or at a higher level in malignant tissues than the normal counterpart across multiple clinical studies evaluating oncolytic MV: the tumor biopsies from 5 out of 5 patients with cutaneous T-cell lymphomas tested positive for CD46 (109), 13 out of 15 patients with ovarian cancer showed high expression level of CD46 (110), and CD138+ myeloma cells from patients were shown to express higher level of CD46 than CD138- normal counterpart (111). This evidence concerns the gene CD46 and plasma cell myeloma.